{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/prescribing-information/proton-pump-inhibitors/","result":{"pageContext":{"chapter":{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors","depth":2,"htmlHeader":"<!-- begin field 95e6159f-73fb-4cc3-beff-46bf52d626a8 --><h2>Proton pump inhibitors</h2><!-- end field 95e6159f-73fb-4cc3-beff-46bf52d626a8 -->","summary":"","htmlStringContent":"<!-- begin item 8180faa5-72df-4c49-a817-b138dc6b4557 --><!-- end item 8180faa5-72df-4c49-a817-b138dc6b4557 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","lastRevised":"Last revised in October 2019","chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","fullItemName":"Management","slug":"management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b1f97702-e336-5782-be09-a8f41901cd34","slug":"choice-of-proton-pump-inhibitor","fullItemName":"Choice of proton pump inhibitor","depth":3,"htmlHeader":"<!-- begin field 658b77e6-5a40-45d4-815a-5445a9a478d5 --><h3>Choice of proton pump inhibitor</h3><!-- end field 658b77e6-5a40-45d4-815a-5445a9a478d5 -->","summary":"","htmlStringContent":"<!-- begin item 62aae9ee-16b3-489b-bc1e-8dbe41998777 --><!-- begin field 49d977f8-bedd-4188-81fd-8d0a7827f3cb --><ul><li>Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with dyspepsia symptoms.</li></ul><p><strong>Table 1</strong><strong>. </strong>PPI doses for the management of people with dyspepsia symptoms.</p><table><thead><tr><th colspan=\"1\"><p>PPI</p></th><th colspan=\"1\"><p>Full or standard dose</p></th><th colspan=\"1\"><p>Low dose (on-demand dose)</p></th><th colspan=\"1\"><p>Double dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Omeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 10 mg once a day</td><td colspan=\"1\">40 mg once a day</td></tr><tr><td colspan=\"1\">Lansoprazole</td><td colspan=\"1\">30 mg once a day</td><td colspan=\"1\">15 mg once a day</td><td colspan=\"1\">* 30 mg twice a day</td></tr><tr><td colspan=\"1\">Pantoprazole</td><td colspan=\"1\">40 mg once a day</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 40 mg twice a day</td></tr><tr><td colspan=\"1\">Rabeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">* 20 mg twice a day</td></tr><tr><td colspan=\"1\">Esomeprazole</td><td colspan=\"1\">† 20 mg once a day</td><td colspan=\"1\">Not available</td><td colspan=\"1\">‡ 40 mg once a day</td></tr><tr><td colspan=\"4\">Doses should be given 30 minutes before breakfast and (if needed) 30 minutes before the evening meal, to provide optimal control of gastric pH.</td></tr><tr><td colspan=\"4\">* Off-label dose for GORD.</td></tr><tr><td colspan=\"4\">† This is lower than the licensed starting dose in GORD, but is considered to be dose-equivalent to other PPIs.</td></tr><tr><td colspan=\"4\">‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg.</td></tr><tr><td colspan=\"4\"><strong>Data from: [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">NICE, 2014</a>]</strong></td></tr></tbody></table><!-- end field 49d977f8-bedd-4188-81fd-8d0a7827f3cb --><!-- end item 62aae9ee-16b3-489b-bc1e-8dbe41998777 -->","subChapters":[]},{"id":"885b9626-e1d9-595a-b661-149c88b183a7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ffd6fd40-3607-40b3-bc6c-596e70dda622 --><h3>Contraindications and cautions</h3><!-- end field ffd6fd40-3607-40b3-bc6c-596e70dda622 -->","summary":"","htmlStringContent":"<!-- begin item d7a72e19-f13e-4a7e-968e-f94675ecb0d5 --><!-- begin field ee774728-823a-4ed9-bebc-f00d6316f40e --><ul><li><strong>Proton pump inhibitors (PPIs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as PPIs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking a PPI and subsequently needs an endoscopy, the PPI should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>PPIs should be prescribed with caution to people:</strong><ul><li>At risk of osteoporosis — the person should maintain an adequate intake of calcium and vitamin D, and if necessary, be given additional bone-sparing therapy.</li><li>At risk of hypomagnesaemia — if possible, magnesium levels should be checked before starting PPI therapy and intermittently during long-term treatment, for example if the person is prescribed drugs that can cause hypomagnesaemia, such as digoxin and diuretics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">MHRA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field ee774728-823a-4ed9-bebc-f00d6316f40e --><!-- end item d7a72e19-f13e-4a7e-968e-f94675ecb0d5 -->","subChapters":[]},{"id":"a886fa97-a010-5c1c-939a-fcd9fb8d2c30","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field dc017660-82f1-462b-ad94-4dad9eede34b --><h3>Adverse effects</h3><!-- end field dc017660-82f1-462b-ad94-4dad9eede34b -->","summary":"","htmlStringContent":"<!-- begin item e46912c7-f4b8-48bb-a3d3-192ec95cb584 --><!-- begin field 9da99f90-77ea-4c13-9242-5d2fd7428eb7 --><p><strong>Adverse effects of proton pump inhibitors (PPIs) are usually mild and reversible.</strong></p><ul><li>Adverse effects include headache, diarrhoea, nausea, vomiting, abdominal pain, constipation, and dizziness.</li><li>Less common adverse effects include dry mouth, peripheral oedema, sleep disturbance, fatigue, paraesthesia, arthralgia, myalgia, pruritus, and rash.</li><li>Rare or very rare adverse effects include:<ul><li>Subacute cutaneous lupus erythematosus (SCLE), which can occur weeks, months, or years after exposure to a PPI. If suspected discontinue the PPI and seek specialist advice if needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">MHRA, 2015</a>].</li><li>Taste disturbance, hepatitis, jaundice, depression, confusion, hallucinations, hyponatraemia, leucopenia, leucocytosis, pancytopenia, thrombocytopenia, visual disturbances, sweating, photophobia, and alopecia.</li></ul></li><li>Long-term PPI treatment may be associated with uncommon, serious adverse effects such as:<ul><li>Hypomagnesaemia — symptoms include muscle twitching, tremors, vomiting, fatigue, and loss of appetite. Case reports after one year of PPI therapy, but may occur after 3 months. This usually improves after magnesium replacement therapy and discontinuation of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">MHRA, 2012</a>].</li><li>Increased risk of fractures — especially when used at high doses for over a year in the elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">MHRA, 2012</a>].</li><li><em>Clostridium difficile </em>infection — due to the effect of decreasing gastric acidity.</li><li>Rebound acid hypersecretion syndrome — may occur after stopping long-term PPI therapy, although this may be more a theoretical risk than clinical phenomenon.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field 9da99f90-77ea-4c13-9242-5d2fd7428eb7 --><!-- end item e46912c7-f4b8-48bb-a3d3-192ec95cb584 -->","subChapters":[]},{"id":"1d1697cc-738e-5f2d-b466-e287adfe1bfe","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fa002a5f-5620-44b2-81dc-591b1a57c5d3 --><h3>Drug interactions</h3><!-- end field fa002a5f-5620-44b2-81dc-591b1a57c5d3 -->","summary":"","htmlStringContent":"<!-- begin item 3177b08e-d8b4-4f01-b8ae-b1c40d66113e --><!-- begin field ef572839-0f96-4f9f-8697-2e459fc32502 --><p><strong>Possible drug interactions with proton pump inhibitors (PPIs) include:</strong></p><ul><li><strong>Digoxin </strong>— PPIs may cause a small rise in serum digoxin levels (although not considered clinically significant). The manufacturer of lansoprazole suggests that digoxin levels should be monitored if lansoprazole is started or stopped.</li><li><strong>Warfarin </strong>— PPIs can occasionally enhance the effects of warfarin. The<strong> </strong>international normalized ratio (INR) should be monitored in people taking warfarin if omeprazole, pantoprazole, or esomeprazole is started or stopped.</li><li><strong>Methotrexate </strong>— PPIs possibly reduce excretion of methotrexate, leading to an increased risk of methotrexate toxicity.</li><li><strong>Phenytoin</strong> — omeprazole and esomeprazole can occasionally enhance the effects of phenytoin.<strong> </strong>The manufacturers recommend that people taking phenytoin are carefully monitored if omeprazole or esomeprazole is started or stopped.</li><li><strong>Azole antifungals</strong> — the absorption of ketoconazole or itraconazole may be reduced during PPI treatment. Dose adjustment of the antifungal drug may be required during long-term PPI treatment.</li><li><strong>Clopidogrel </strong>— omeprazole and esomeprazole reduce the antiplatelet effect of clopidogrel, and concomitant use should be avoided. The other PPIs may also reduce the efficacy of clopidogrel, and this risk should be weighed against the potential benefit of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">MHRA, 2010</a>].</li><li><strong>Protease inhibitors </strong>— PPIs can significantly affect plasma levels of some protease inhibitor drugs, including:<ul><li>Atazanavir — concurrent use of PPIs and atazanavir is not recommended as the absorption of atazanavir may be affected by a PPI (due to changes in gastric acidity). This may lead to a reduced plasma concentration of atazanavir which may affect its efficacy. If concurrent use is necessary, seek specialist advice.</li><li>Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects.</li><li>Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field ef572839-0f96-4f9f-8697-2e459fc32502 --><!-- end item 3177b08e-d8b4-4f01-b8ae-b1c40d66113e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}